دورية أكاديمية
Online survey of medicinal cannabis users: Qualitative analysis of patient-level data.
| العنوان: | Online survey of medicinal cannabis users: Qualitative analysis of patient-level data. |
|---|---|
| المؤلفون: | Garcia-Romeu A; Johns Hopkins University School of Medicine, Baltimore, MD, United States., Elmore J; University of Colorado Boulder, Boulder, CO, United States., Mayhugh RE; Johns Hopkins University School of Medicine, Baltimore, MD, United States., Schlienz NJ; Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States., Martin EL; Medical University of South Carolina, Charleston, SC, United States., Strickland JC; Johns Hopkins University School of Medicine, Baltimore, MD, United States., Bonn-Miller M; Canopy Growth Corporation, Smiths Falls, ON, Canada., Jackson H; Realm of Caring Foundation, Colorado Springs, Colorado, CO, United States., Vandrey R; Johns Hopkins University School of Medicine, Baltimore, MD, United States. |
| المصدر: | Frontiers in pharmacology [Front Pharmacol] 2022 Sep 06; Vol. 13, pp. 965535. Date of Electronic Publication: 2022 Sep 06 (Print Publication: 2022). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Media] |
| مستخلص: | Aim: To characterize perceived benefits and challenges experienced by medicinal cannabis users. Methods: An anonymous online survey collected demographics, health information, and open-ended responses from medicinal cannabis users regarding perceptions, motivations, and experience of treatment. Qualitative open-ended responses were thematically analyzed. Results: Respondents ( N = 808) were predominantly White (79%), female (63%), with a mean (SD) age of 38 (20). Two hundred eighty-four (35%) respondents provided data on a dependent family member (e.g., child; 22% of total sample). Most used cannabidiol (CBD)-dominant products (58%), primarily for neurological disorders (38%) or pain (25%). Primary motivations for medicinal cannabis use were based on beliefs that traditional treatments were ineffective and/or had intolerable side effects (51%), positive scientific or media portrayals of the safety/efficacy of cannabis as a therapeutic (29%), or preference for "natural" treatments over pharmaceuticals (21%). A majority of respondents (77%) attributed positive effects to the medicinal use of cannabis/cannabinoids. These included physical symptom improvements such as reduced pain (28%), improved sleep (18%), and seizure reduction (18%), and mental health improvements including reduced anxiety (22%) and improved mood (11%). Additionally, respondents reported reduced use of other medications (e.g., opioids) (12%), and improved quality of life (14%). Problems associated with use were cited by 41% of respondents, and included unwanted side effects (16%), lack of information or medical support (16%), prohibitive costs (12%), and legal concerns (10%). Conclusion: Most participants reported benefits from cannabis use for a variety of conditions where traditional treatments were ineffective or unacceptable. Concerns regarding cannabis side effects, legality, lack of information, and cost were raised. Data indicate greater research and education on the safety and efficacy of medicinal cannabis/cannabinoid use is warranted. Competing Interests: AG-R is a scientific advisor to Etha Natural Botanicals, Innerwell, and NeonMind Biosciences. RV has received compensation as a consultant or scientific advisor from MyMD Pharmaceuticals, Mira1a Pharmaceuticals Inc. Canopy Health Innovations, Syqe Medical Ltd. WebMD, and Radicle Science Inc. MB-M is employed by Canopy Growth Corporation. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Garcia-Romeu, Elmore, Mayhugh, Schlienz, Martin, Strickland, Bonn-Miller, Jackson and Vandrey.) |
| References: | Int Rev Psychiatry. 2018 Jun;30(3):181-182. (PMID: 30179536) Eur J Pain. 2014 Aug;18(7):999-1012. (PMID: 24420962) Curr Opin Psychol. 2019 Dec;30:98-102. (PMID: 31071592) Epilepsy Behav. 2021 Sep;122:108205. (PMID: 34311183) J Neurol Sci. 2020 Apr 15;411:116717. (PMID: 32044684) J Pain. 2015 Jul;16(7):616-27. (PMID: 25843054) Pain. 2018 Oct;159(10):1932-1954. (PMID: 29847469) Addict Behav. 2016 Oct;61:99-103. (PMID: 27262964) JAMA. 2017 Jan 10;317(2):209-211. (PMID: 27992636) Biochem Med (Zagreb). 2012;22(3):276-82. (PMID: 23092060) Lancet. 2019 Oct 26;394(10208):1580-1590. (PMID: 31657733) Epilepsia. 2007;48 Suppl 1:3-7. (PMID: 17316406) Epilepsy Behav. 2015 Jun;47:138-41. (PMID: 25935511) J Pain Res. 2016 Aug 31;9:587-98. (PMID: 27621666) PLoS One. 2018 Mar 1;13(3):e0193959. (PMID: 29494708) Pain Physician. 2008 Mar;11(2 Suppl):S105-20. (PMID: 18443635) Prim Care Companion J Clin Psychiatry. 2001 Feb;3(1):22-27. (PMID: 15014625) Cannabis Cannabinoid Res. 2019 Sep 23;4(3):139-157. (PMID: 31579832) Curr Med Res Opin. 2007 Mar;23(3):533-43. (PMID: 17355735) Front Psychiatry. 2021 Sep 09;12:729800. (PMID: 34566726) J Psychoactive Drugs. 2019 Nov-Dec;51(5):400-404. (PMID: 31264536) Lancet Neurol. 2012 Sep;11(9):792-802. (PMID: 22832500) Lancet. 2003 Nov 8;362(9395):1517-26. (PMID: 14615106) Cannabis Cannabinoid Res. 2022 Apr;7(2):214-223. (PMID: 33998874) Eur J Intern Med. 2018 Mar;49:37-43. (PMID: 29482741) Br J Pharmacol. 2011 Aug;163(7):1344-64. (PMID: 21749363) J Clin Psychiatry. 2009;70 Suppl 6:10-5. (PMID: 19922739) Cannabis Cannabinoid Res. 2021 Dec;6(6):548-558. (PMID: 33998852) Syst Rev. 2019 Dec 10;8(1):320. (PMID: 31823819) Pharmacol Biochem Behav. 1990 Nov;37(3):561-5. (PMID: 1965045) Lancet Psychiatry. 2019 Dec;6(12):995-1010. (PMID: 31672337) JAMA. 2015 Jun 23-30;313(24):2456-73. (PMID: 26103030) J Nat Prod. 2009 May 22;72(5):906-11. (PMID: 19344127) Life Sci. 2005 Dec 22;78(5):539-48. (PMID: 16199061) |
| فهرسة مساهمة: | Keywords: CBD-cannabidiol; THC-tetrahydrocannabinol; cannabis (marijuana); medical marijuana; qualitative |
| تواريخ الأحداث: | Date Created: 20220923 Latest Revision: 20220924 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC9485457 |
| DOI: | 10.3389/fphar.2022.965535 |
| PMID: | 36147312 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!